- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/52 - Purines, e.g. adenine
Patent holdings for IPC class A61K 31/52
Total number of patents in this class: 2800
10-year publication summary
|
196
|
220
|
225
|
204
|
216
|
201
|
161
|
187
|
154
|
99
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10856 |
48 |
| The Regents of the University of California | 19887 |
44 |
| Gilead Sciences, Inc. | 2036 |
28 |
| Merck Sharp & Dohme LLC | 3749 |
28 |
| Infinity Pharmaceuticals, Inc. | 99 |
27 |
| Boehringer Ingelheim International GmbH | 4665 |
25 |
| Merck Sharp & Dohme Corp. | 2198 |
24 |
| Signal Pharmaceuticals, LLC | 179 |
23 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2847 |
23 |
| Epizyme, Inc. | 370 |
21 |
| F. Hoffmann-La Roche AG | 7930 |
20 |
| Amgen Inc. | 4073 |
20 |
| The Johns Hopkins University | 5662 |
20 |
| Dana-Farber Cancer Institute, Inc. | 2562 |
20 |
| Centre National de La Recherche Scientifique | 10418 |
19 |
| Intellikine LLC | 42 |
19 |
| K36 Therapeutics, Inc. | 22 |
19 |
| Rhizen Pharmaceuticals AG | 56 |
18 |
| Incyte Corporation | 1020 |
16 |
| Celgene Corporation | 1400 |
15 |
| Other owners | 2323 |